Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

4.2%

1 terminated out of 24 trials

Success Rate

80.0%

-6.6% vs benchmark

Late-Stage Pipeline

13%

3 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed with results

Key Signals

80% success

Data Visualizations

Phase Distribution

20Total
Not Applicable (3)
P 1 (11)
P 2 (3)
P 3 (3)

Trial Status

Recruiting8
Not Yet Recruiting7
Completed4
Active Not Recruiting2
Unknown1
Withdrawn1

Trial Success Rate

80.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (24)

Showing 20 of 20 trials
NCT07800507Phase 1Not Yet RecruitingPrimary

Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer

NCT05014139Phase 1Terminated

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

NCT07798479Completed

Age and Bladder Cancer Outcomes After BCG Treatment: A Multicenter Study

NCT07763197Recruiting

Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)

NCT05483868Phase 1Active Not Recruiting

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

NCT07725796Phase 1Not Yet Recruiting

A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

NCT07207824Phase 3Recruiting

DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC

NCT07424287Phase 3RecruitingPrimary

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

NCT07551544Phase 3WithdrawnPrimary

ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer

NCT06810141UnknownPrimary

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

NCT07505615Phase 1CompletedPrimary

A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

NCT06800963Phase 1RecruitingPrimary

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

NCT07445308Phase 1Not Yet RecruitingPrimary

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

NCT05375903Phase 1Completed

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

NCT03914794Phase 2Completed

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

NCT06181266Phase 1Active Not RecruitingPrimary

A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

NCT07064863Phase 1Not Yet RecruitingPrimary

A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.

NCT06991868RecruitingPrimary

A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)

NCT06982690Not ApplicableNot Yet RecruitingPrimary

Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial

NCT06889623Not ApplicableRecruitingPrimary

Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer

Scroll to load more

Research Network

Activity Timeline